CA3248736A1 - CRYSTALLINE PROSTACYCLINE (IP) RECEPTOR AGONIST AND ITS USES - Google Patents

CRYSTALLINE PROSTACYCLINE (IP) RECEPTOR AGONIST AND ITS USES

Info

Publication number
CA3248736A1
CA3248736A1 CA3248736A CA3248736A CA3248736A1 CA 3248736 A1 CA3248736 A1 CA 3248736A1 CA 3248736 A CA3248736 A CA 3248736A CA 3248736 A CA3248736 A CA 3248736A CA 3248736 A1 CA3248736 A1 CA 3248736A1
Authority
CA
Canada
Prior art keywords
ralinepag
theta
crystalline form
xrpd
pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3248736A
Other languages
English (en)
French (fr)
Inventor
Kenneth Phares
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of CA3248736A1 publication Critical patent/CA3248736A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/08—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3248736A 2022-02-15 2023-02-14 CRYSTALLINE PROSTACYCLINE (IP) RECEPTOR AGONIST AND ITS USES Pending CA3248736A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263310469P 2022-02-15 2022-02-15
US63/310,469 2022-02-15
PCT/US2023/013032 WO2023158634A1 (en) 2022-02-15 2023-02-14 Crystalline prostacyclin (ip) receptor agonist and uses thereof

Publications (1)

Publication Number Publication Date
CA3248736A1 true CA3248736A1 (en) 2023-08-24

Family

ID=87578956

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3248736A Pending CA3248736A1 (en) 2022-02-15 2023-02-14 CRYSTALLINE PROSTACYCLINE (IP) RECEPTOR AGONIST AND ITS USES

Country Status (9)

Country Link
US (2) US12098116B2 (enExample)
EP (1) EP4479374A1 (enExample)
JP (1) JP2025506098A (enExample)
KR (1) KR20240149924A (enExample)
CN (1) CN118922402A (enExample)
AU (1) AU2023222747A1 (enExample)
CA (1) CA3248736A1 (enExample)
IL (1) IL314717A (enExample)
WO (1) WO2023158634A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
IL320516A (en) 2022-10-31 2025-06-01 United Therapeutics Corp Methods for treating pulmonary hypertension
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945530A1 (de) 1979-11-10 1981-06-04 Chemische Werke Hüls AG, 4370 Marl Harnstoffe mit cyclischen substituenten, ihre herstellung und verwendung als herbizide
JPH03160438A (ja) 1989-11-20 1991-07-10 Konica Corp ハロゲン化銀カラー写真感光材料
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
CA2085844A1 (en) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
JPH06329598A (ja) 1993-05-19 1994-11-29 Daicel Chem Ind Ltd エステルの製造方法
DE4318889A1 (de) 1993-06-07 1994-12-08 Bayer Ag Verfahren zur Herstellung von organischen Carbamaten
KR100383305B1 (ko) 1994-03-10 2003-11-01 후지사와 야꾸힝 고교 가부시키가이샤 프로스타글란딘i₂작용물질로서의나프탈렌유도체
JPH11269138A (ja) 1998-03-20 1999-10-05 Mitsubishi Paper Mills Ltd 有機塩基発生剤
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
EP1046631A1 (en) 1999-04-19 2000-10-25 Rolic AG Liquid crystalline compounds
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
YU68102A (sh) 2000-03-16 2006-01-16 F. Hoffmann-La Roche Ag. Derivati karboksilne kiseline kao ip antagonisti
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
TWI316055B (enExample) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
AU2002322585A1 (en) 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
NZ531153A (en) 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
CN1735598A (zh) 2002-11-11 2006-02-15 拜耳医药保健股份公司 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
EP1603878B1 (en) 2003-02-10 2013-01-02 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
GB0317498D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Compounds
BRPI0414630A (pt) 2003-09-22 2006-11-07 Hoffmann La Roche derivados ciclohexìlicos substituìdos com aminoalquilamida
JP4402413B2 (ja) 2003-09-29 2010-01-20 財団法人２１あおもり産業総合支援センター Ｕ字型化合物およびこれを含む液晶組成物
DE102004006785A1 (de) 2004-02-11 2005-09-08 Mayr, Herbert, Prof. Dr. Verfahren zur CC-Bindungsknüpfung zwischen elektrophilen Substraten und TT-Verbindungen in neutralen bis basischen wässrigen oder alkoholischen Lösungsmitteln ohne den Einsatz einer Lewis- oder Protonensäure
JP2008510726A (ja) 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
JP2006083085A (ja) 2004-09-15 2006-03-30 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体の製造法およびその合成中間体
JP4792731B2 (ja) 2004-11-12 2011-10-12 Ｄｉｃ株式会社 重合性液晶組成物及び当該組成物の硬化物
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
JP2007161867A (ja) 2005-12-14 2007-06-28 Toyo Ink Mfg Co Ltd インキ組成物
AU2007249827A1 (en) 2006-05-09 2007-11-22 Colorado State University Research Foundation Methods for treating blood disorders
CN110003123B (zh) 2008-03-18 2023-06-23 艾尼纳制药公司 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
AU2009325117C1 (en) 2008-11-26 2014-12-18 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
EP2370413B1 (en) 2008-12-08 2015-08-05 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
WO2011037613A1 (en) 2009-09-23 2011-03-31 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
MX394186B (es) 2014-10-23 2025-03-24 Arena Pharm Inc Metodo de tratamiento de afecciones relacionadas con el receptor pgi2
KR20230021186A (ko) 2016-11-10 2023-02-13 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
EP3977985B1 (en) 2017-03-01 2023-09-06 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
JP7343478B2 (ja) 2017-08-07 2023-09-12 アレーナ ファーマシューティカルズ，インク． 処置の方法
KR20210040837A (ko) 2018-05-16 2021-04-14 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
CN112638865B (zh) * 2018-09-06 2022-07-26 广东东阳光药业有限公司 药物共晶体及其制备方法
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
EP4493540A4 (en) 2022-03-17 2026-02-18 United Therapeutics Corp RALINEPAG MEDICATIONS AND THEIR USES

Also Published As

Publication number Publication date
JP2025506098A (ja) 2025-03-07
AU2023222747A1 (en) 2024-08-22
US20230406815A1 (en) 2023-12-21
WO2023158634A1 (en) 2023-08-24
US20240409503A1 (en) 2024-12-12
KR20240149924A (ko) 2024-10-15
EP4479374A1 (en) 2024-12-25
US12098116B2 (en) 2024-09-24
IL314717A (en) 2024-10-01
CN118922402A (zh) 2024-11-08

Similar Documents

Publication Publication Date Title
US12098116B2 (en) Crystalline prostacyclin (IP) receptor agonist and uses thereof
EP1313714B1 (en) Valsartan salts
TWI718104B (zh) AHU-377結晶型游離酸、半鈣鹽、α-苯乙胺鹽及其製備方法和應用
EP3977985B1 (en) Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
AU2005311652B2 (en) Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition
JP2025165933A (ja) サルカルディン塩
AU2005311714B2 (en) Pharmaceutical composition containing an anti-nucleating agent
CN114007689B (zh) 心肌肌钙蛋白活化剂的多晶型物和共晶体
US10654859B2 (en) Methanesulfonate polymorph of 5-type phosphodiesterase inhibitor and preparation method and applications thereof
US20240228462A1 (en) Crystalline forms of n-{3-[(1s)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2- yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide and related products and methods
WO2025193777A1 (en) Pharmaceutical compositions of alpha-1 antitrypsin modulators
HK40072274B (en) Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
US20220273572A1 (en) Solid formulation of a 1,2,4-oxadiazole derivative
HK40068824A (en) Polymorphs and cocrystals of a cardiac troponin activator
IL317940A (en) The highly soluble forms of harmine
JP2007051085A (ja) インドリン化合物を含有する安定化された医薬組成物
HK1055963B (en) Valsartan salts

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240715

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241220

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241220

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250110

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250214

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250214

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250221